Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Abstract

The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment or prevention of heart failure of any aetiology.

What is claimed is:  
     
         1 . A method for the treatment or prevention of heart failure, which comprises the administration to a patient in need thereof of a pharmaceutical composition comprising cilobradine or a pharmaceutically acceptable salt thereof, together with a pharmaceutically suitable carrier.  
     
     
         2 . The method of  claim 1  for the prevention of heart failure.  
     
     
         3 . The method of  claim 1  for the treatment of heart failure.  
     
     
         4 . The method of  claim 1  wherein the galenical formulation of the pharmaceutical composition is a tablet, a drinking solution, a capsule, a suppository or an injectable formulation.  
     
     
         5 . The method of  claim 4  wherein the galenical formulation of the pharmaceutical composition is a tablet.  
     
     
         6 . The method of  claim 4  wherein the galenical formulation of the pharmaceutical composition is a drinking solution.  
     
     
         7 . The method of  claim 1  wherein the pharmaceutical composition is administered following a single or multiple stage daily application scheme.  
     
     
         8 . The method of  claim 7  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.01 and 20 mg/kg body weight.  
     
     
         9 . The method of  claim 7  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.05 and 5 mg/kg body weight.  
     
     
         10 . The method of  claim 7  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 2.5 mg/kg body weight.  
     
     
         11 . The method according to  claim 7  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 1 mg/kg body weight.  
     
     
         12 . The method of  claim 7  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 0.75 mg/kg body weight.  
     
     
         13 . The method of  claim 1  wherein the treatment or prevention of heart failure is performed in combination with other therapeutic agents for the treatment or prevention of heart failure.  
     
     
         14 . The method of  claim 13  wherein said therapuuetic agents include diuretics, cardiac glycosides, ACE inhibitors, ARBs, vasodilators, beta blockers or inotropes.